Press releases.

Press releases 2023

Press releases 2023

Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

September 21st 2023

Immutep to Participate in September Investor Conferences

September 5th 2023

Immutep Receives Positive Scientific Advice from European Medicines Agency

August 1st 2023

Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023

July 31st 2023

Immutep Quarterly Activities Report Q4 FY23

July 31st 2023

First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

July 28th 2023

Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor

June 27th 2023

Immutep Completes A$80 Million Capital Raise

June 27th 2023

Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3

June 20th 2023

Immutep to Participate at the Jefferies Healthcare Conference

June 7th 2023

Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting

June 5th 2023

Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer

June 2nd 2023

Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study

May 29th 2023

Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting

May 26th 2023

Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

May 25th 2023

Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial

May 24th 2023

Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

May 17th 2023

Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

May 16th 2023

Immutep to Participate in the JMP Securities Life Sciences Conference

May 9th 2023

Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma

May 2nd 2023

Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®

May 1st 2023

Immutep Quarterly Activities Report

April 27th 2023

Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting

April 26th 2023

Immutep Appoints Dr. Florian Vogl as Chief Medical Officer

April 26th 2023

Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting

April 17th 2023

Immutep Announces Changes to the Board

April 11th 2023

Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023

March 31st 2023

Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer

March 30th 2023

Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023

March 23rd 2023

Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer

March 14th 2023

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

February 6th 2023

Immutep Quarterly Activities Report

January 30th 2023

Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer

January 4th 2023